[{"id":"6e8fbd0c-23f7-46c6-93fc-7a144127a44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05764395","created_at":"2023-03-10T15:01:42.443Z","updated_at":"2024-07-02T16:34:36.730Z","phase":"Phase 2","brief_title":"Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors","source_id_and_acronym":"NCT05764395","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Estybon (rigosertib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-10"},{"id":"8934f0cb-e0b1-4008-8421-763be12314d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383196","created_at":"2022-05-20T18:58:19.196Z","updated_at":"2024-07-02T16:35:02.611Z","phase":"Phase 1/2","brief_title":"Onvansertib + Paclitaxel In TNBC","source_id_and_acronym":"NCT05383196","lead_sponsor":"Antonio Giordano, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • onvansertib (PCM-075)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 02/15/2026","primary_completion_date":" 02/15/2026","study_txt":" Completion: 02/15/2029","study_completion_date":" 02/15/2029","last_update_posted":"2024-05-20"},{"id":"bccdf47b-f667-4740-8dce-142e2428e515","acronym":"","url":"https://clinicaltrials.gov/study/NCT04263090","created_at":"2021-01-18T20:43:01.463Z","updated_at":"2025-02-25T14:29:03.672Z","phase":"Phase 1/2","brief_title":"Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment","source_id_and_acronym":"NCT04263090","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Estybon (rigosertib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-05-09"},{"id":"661d65c0-b705-4f26-9720-4dc72aa20c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT06106308","created_at":"2023-10-30T16:12:32.775Z","updated_at":"2024-07-02T16:35:06.108Z","phase":"Phase 2","brief_title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","source_id_and_acronym":"NCT06106308","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/27/2024","start_date":" 02/27/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-03"},{"id":"78a25275-44d9-4dd0-a5b4-65a103b2a67e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03829410","created_at":"2021-01-17T17:16:00.145Z","updated_at":"2024-07-02T16:35:16.847Z","phase":"Phase 1/2","brief_title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation","source_id_and_acronym":"NCT03829410","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS exon 2 mutation","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/06/2019","start_date":" 05/06/2019","primary_txt":" Primary completion: 01/29/2024","primary_completion_date":" 01/29/2024","study_txt":" Completion: 01/29/2024","study_completion_date":" 01/29/2024","last_update_posted":"2024-03-01"},{"id":"dad0c4dd-09a2-4451-b67d-87c0d6cf6455","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446793","created_at":"2021-01-18T21:23:54.941Z","updated_at":"2024-07-02T16:35:19.823Z","phase":"","brief_title":"Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04446793","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-12"},{"id":"29615e37-bb63-4054-a44c-541e878490a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05358379","created_at":"2024-02-07T19:21:22.852Z","updated_at":"2024-07-02T16:35:20.542Z","phase":"Phase 1/2","brief_title":"A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma","source_id_and_acronym":"NCT05358379","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" PLK1 • CDKN1A","pipe":" | ","alterations":" MYC expression","tags":["PLK1 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-02-07"},{"id":"7aeffcc1-8575-4ac7-bef5-83f3bb3a65fa","acronym":"ONSEMBLE","url":"https://clinicaltrials.gov/study/NCT05593328","created_at":"2022-10-25T13:56:27.583Z","updated_at":"2024-07-02T16:35:23.267Z","phase":"Phase 2","brief_title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation","source_id_and_acronym":"NCT05593328 - ONSEMBLE","lead_sponsor":"Cardiff Oncology","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/17/2023","start_date":" 03/17/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-17"},{"id":"0e10acf9-5a67-407c-ab46-05c9fe46a0db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00710710","created_at":"2021-07-05T16:04:35.612Z","updated_at":"2024-07-02T16:36:11.025Z","phase":"Phase 2","brief_title":"Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer","source_id_and_acronym":"NCT00710710","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BI2536"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 10/14/2008","primary_completion_date":" 10/14/2008","study_txt":" Completion: 10/14/2008","study_completion_date":" 10/14/2008","last_update_posted":"2022-05-04"},{"id":"8b936338-8214-4e74-b918-526c622c7c6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00861328","created_at":"2021-01-18T03:17:03.343Z","updated_at":"2024-07-02T16:37:20.692Z","phase":"Phase 1","brief_title":"Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin","source_id_and_acronym":"NCT00861328","lead_sponsor":"Onconova Therapeutics, Inc.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Estybon (rigosertib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 02/01/2008","start_date":" 02/01/2008","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 07/01/2011","study_completion_date":" 07/01/2011","last_update_posted":"2017-06-23"}]